Abstract
Twelve volunteers received 300 mg of clindamycin intravenously (i.v.) or orally (p.o.) administered every 8 h (q8h) or q12h by random assignment over four study periods. Serum bactericidal titers were determined for each regimen against two isolates each of Staphylococcus aureus, Streptococcus pneumoniae (one penicillin-sensitive isolate and one penicillin-resistant isolate), and Bacteroides fragilis. The duration of measurable bactericidal activity over the dosing interval (expressed as a percentage of the dosing interval) was determined for each isolate. No significant differences in the duration of activity were observed between i.v. and p.o. regimens dosed according to the same interval (P > 0.05). All regimens provided bactericidal activity against S. pneumoniae for 100% of their respective dosing intervals. Against B. fragilis, bactericidal activity was observed for greater than 80% of the dosing interval for each of the regimens. Although a statistically significant difference favoring the q8h i.v. regimen (P < 0.05) was detected, this difference is not believed to be clinically significant. The q8h and q12h regimens provided measurable bactericidal activity against S. aureus for greater than 85 and 50% of the dosing intervals, respectively (P < 0.001). Clindamycin dosed at 300 mg i.v. or p.o., q8h or q12h, provides adequate coverage against S. aureus, S. pneumoniae, and B. fragilis.
Full Text
The Full Text of this article is available as a PDF (162.8 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Ameer B., Sesin P., Karchmer A. W. Selecting clindamycin dosage regimens. Am J Hosp Pharm. 1987 Sep;44(9):2027–2028. [PubMed] [Google Scholar]
- Chin A., Gill M. A., Ito M. K., Yellin A. E., Berne T. V., Heseltine P. N., Appleman M. D., Chenella F. C. Evaluation of two different dosage regimens of clindamycin and the penetration into human appendix. Ther Drug Monit. 1989;11(4):421–424. [PubMed] [Google Scholar]
- Craig W. A. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis. 1995 May-Jun;22(1-2):89–96. doi: 10.1016/0732-8893(95)00053-d. [DOI] [PubMed] [Google Scholar]
- Flaherty J. F., Rodondi L. C., Guglielmo B. J., Fleishaker J. C., Townsend R. J., Gambertoglio J. G. Comparative pharmacokinetics and serum inhibitory activity of clindamycin in different dosing regimens. Antimicrob Agents Chemother. 1988 Dec;32(12):1825–1829. doi: 10.1128/aac.32.12.1825. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gatti G., Flaherty J., Bubp J., White J., Borin M., Gambertoglio J. Comparative study of bioavailabilities and pharmacokinetics of clindamycin in healthy volunteers and patients with AIDS. Antimicrob Agents Chemother. 1993 May;37(5):1137–1143. doi: 10.1128/aac.37.5.1137. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Klepser M. E., Banevicius M. A., Quintiliani R., Nightingale C. H. Characterization of bactericidal activity of clindamycin against Bacteroides fragilis via kill curve methods. Antimicrob Agents Chemother. 1996 Aug;40(8):1941–1944. doi: 10.1128/aac.40.8.1941. [DOI] [PMC free article] [PubMed] [Google Scholar]
- McDonald P. J., Craig W. A., Kunin C. M. Persistent effect of antibiotics on Staphylococcus aureus after exposure for limited periods of time. J Infect Dis. 1977 Feb;135(2):217–223. doi: 10.1093/infdis/135.2.217. [DOI] [PubMed] [Google Scholar]
- Plaisance K. I., Drusano G. L., Forrest A., Townsend R. J., Standiford H. C. Pharmacokinetic evaluation of two dosage regimens of clindamycin phosphate. Antimicrob Agents Chemother. 1989 May;33(5):618–620. doi: 10.1128/aac.33.5.618. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Townsend R. J., Baker R. P. Pharmacokinetic comparison of three clindamycin phosphate dosing schedules. Drug Intell Clin Pharm. 1987 Mar;21(3):279–281. doi: 10.1177/106002808702100310. [DOI] [PubMed] [Google Scholar]
- Xue I. B., Davey P. G., Phillips G. Variation in postantibiotic effect of clindamycin against clinical isolates of Staphylococcus aureus and implications for dosing of patients with osteomyelitis. Antimicrob Agents Chemother. 1996 Jun;40(6):1403–1407. doi: 10.1128/aac.40.6.1403. [DOI] [PMC free article] [PubMed] [Google Scholar]